News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
170,224 Results
Type
Article (6865)
Company Profile (110)
Press Release (163249)
Multimedia
Podcasts (47)
Webinars (7)
Section
Business (53861)
Career Advice (356)
Deals (9765)
Drug Delivery (30)
Drug Development (31987)
Employer Resources (69)
FDA (2739)
Job Trends (4150)
News (96577)
Policy (6770)
Tag
2024 BioCapital Digital (3)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (4)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Biotech Bay Standard (6)
2024 Biotech Beach Digital (2)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (260)
Accelerated approval (1)
Adcomms (2)
Allergies (28)
Alliances (12295)
ALS (34)
Alzheimer's disease (392)
Antibody-drug conjugate (ADC) (56)
Approvals (2761)
Artificial intelligence (74)
Autoimmune disease (8)
Automation (1)
Bankruptcy (64)
Best Places to Work (3219)
BIOSECURE Act (15)
Biosimilars (42)
Biotechnology (72)
Bladder cancer (18)
Brain cancer (13)
Breast cancer (60)
Cancer (655)
Cardiovascular disease (42)
Career advice (308)
Career pathing (21)
CAR-T (55)
Cell therapy (136)
Cervical cancer (4)
Clinical research (27118)
Collaboration (272)
Compensation (283)
Complete response letters (8)
COVID-19 (659)
CRISPR (8)
C-suite (104)
Cystic fibrosis (25)
Data (754)
Decentralized trials (1)
Denatured (12)
Depression (15)
Diabetes (62)
Diagnostics (603)
Digital health (2)
Diversity (6)
Diversity, equity & inclusion (19)
Drug discovery (31)
Drug pricing (23)
Drug shortages (3)
Duchenne muscular dystrophy (21)
Earnings (23123)
Editorial (27)
Employer branding (10)
Employer resources (60)
Events (33959)
Executive appointments (314)
FDA (3095)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (207)
Gene editing (19)
Generative AI (9)
Gene therapy (68)
GLP-1 (251)
Government (741)
Grass and pollen (1)
Guidances (15)
Healthcare (2314)
Huntington's disease (9)
IgA nephropathy (7)
Immunology and inflammation (35)
Indications (12)
Infectious disease (692)
Inflammatory bowel disease (47)
Inflation Reduction Act (6)
Influenza (7)
Intellectual property (37)
Interviews (58)
IPO (5771)
IRA (14)
Job creations (1025)
Job search strategy (261)
Kidney cancer (5)
Labor market (27)
Layoffs (135)
Leadership (13)
Legal (911)
Liver cancer (23)
Lung cancer (104)
Lymphoma (48)
Machine learning (2)
Management (23)
Manufacturing (118)
MASH (40)
Medical device (445)
Medtech (446)
Mergers & acquisitions (4248)
Metabolic disorders (228)
Multiple sclerosis (30)
NASH (8)
Neurodegenerative disease (28)
Neuropsychiatric disorders (7)
Neuroscience (567)
NextGen: Class of 2025 (980)
Non-profit (239)
Northern California (1072)
Now hiring (29)
Obesity (122)
Opinion (78)
Ovarian cancer (30)
Pain (25)
Pancreatic cancer (21)
Parkinson's disease (41)
Partnered (3)
Patents (72)
Patient recruitment (43)
Peanut (15)
People (17297)
Pharmaceutical (38)
Pharmacy benefit managers (1)
Phase I (8203)
Phase II (12499)
Phase III (9111)
Pipeline (463)
Policy (70)
Postmarket research (510)
Preclinical (3062)
Press Release (19)
Prostate cancer (22)
Psychedelics (12)
Radiopharmaceuticals (111)
Rare diseases (102)
Real estate (1203)
Recruiting (29)
Regulatory (5733)
Reports (22)
Research institute (282)
Resumes & cover letters (40)
RNA editing (1)
RSV (13)
Schizophrenia (39)
Series A (35)
Series B (23)
Service/supplier (4)
Sickle cell disease (8)
Southern California (846)
Special edition (16)
Spinal muscular atrophy (43)
Sponsored (5)
Startups (959)
State (1)
Stomach cancer (1)
Supply chain (17)
Tariffs (19)
The Weekly (34)
United States (8013)
Vaccines (164)
Venture capitalists (16)
Weight loss (58)
Women's health (7)
Worklife (12)
Date
Today (23)
Last 7 days (151)
Last 30 days (870)
Last 365 days (11694)
2025 (3422)
2024 (12552)
2023 (14345)
2022 (16202)
2021 (17842)
2020 (15212)
2019 (10001)
2018 (7149)
2017 (8948)
2016 (7308)
2015 (9302)
2014 (7062)
2013 (5085)
2012 (4915)
2011 (4844)
2010 (4810)
Location
Africa (165)
Alabama (18)
Arizona (19)
Arkansas (2)
Asia (13561)
Australia (1487)
California (2235)
Canada (520)
China (316)
Colorado (81)
Connecticut (90)
Delaware (74)
Europe (24545)
Florida (284)
Georgia (71)
Idaho (3)
Illinois (107)
India (8)
Indiana (83)
Iowa (5)
Japan (60)
Kansas (52)
Kentucky (7)
Maine (2)
Maryland (236)
Massachusetts (1789)
Michigan (35)
Minnesota (77)
Missouri (17)
Nebraska (6)
Nevada (4)
New Hampshire (4)
New Jersey (813)
New Mexico (7)
New York (763)
North Carolina (356)
Northern California (1072)
Ohio (68)
Oklahoma (4)
Oregon (12)
Pennsylvania (415)
Puerto Rico (7)
Rhode Island (8)
South America (210)
Southern California (846)
Tennessee (8)
Texas (221)
Utah (51)
Virginia (44)
Washington D.C. (14)
Washington State (150)
Wisconsin (9)
170,224 Results for "matinas biopharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
March 12, 2025
·
7 min read
Press Releases
Matinas BioPharma Receives NYSE Noncompliance Notice
January 13, 2025
·
2 min read
Press Releases
Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair
February 7, 2025
·
2 min read
Press Releases
Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors
February 14, 2025
·
7 min read
Pharm Country
Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
Matinas BioPharma Holdings, Inc. announces that James J. Ferguson, M.D., Chief Medical Officer of Matinas, will be presenting two abstracts at the ASGCT 27th Annual Meeting being held May 7-11, 2024 in Baltimore highlighting data from ex vivo, in vitro and in vivo studies evaluating the use of Matinas’ LNC platform for the uptake and targeted delivery of small oligonucleotides.
May 7, 2024
·
6 min read
Business
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
Matinas BioPharma Holdings, Inc. reports financial results for the three months ending March 31, 2024 and provides a business update.
May 9, 2024
·
11 min read
Pharm Country
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
Matinas BioPharma Holdings, Inc. announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston.
May 16, 2024
·
5 min read
Pharm Country
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
Matinas BioPharma Holdings, Inc. announces the recent successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis (flesh-eating disease) that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales.
June 24, 2024
·
6 min read
Pharm Country
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
Matinas BioPharma Holdings, Inc. announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, demonstrated efficacy compared with placebo in treating the pulmonary mucormycosis fungal infections Rhizopus delemar and M. circinelloides f. jenssenii in immunosuppressed mice.
April 30, 2024
·
6 min read
Pharm Country
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal platform delivery technology, announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, will be featured in a fireside chat with David S. Perlin, PhD, a recognized expert in antifungals.
June 13, 2024
·
6 min read
1 of 17,023
Next
